Novel approaches in GVHD therapy

Bone Marrow Transplantation

Volumn 35, Issue , 2005, Pages S65-S67

  Svennilson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Children; Graft versus host disease; Immunosuppression; Mesenchymal stem cells

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PREDNISOLONE; PSORALEN; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LETHALITY; MESENCHYMAL STEM CELL TRANSPLANTATION; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RECURRENCE RISK; REVIEW; SIDE EFFECT; SKIN DISEASE; TERATOGENICITY; TREATMENT FAILURE;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESENCHYMAL STEM CELL TRANSPLANTATION; PUVA THERAPY;

EID: 18144415115     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704850     Document Type: Article

References (18)

1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
2. Ringdén O, Hermans J, Labopin M et al, for the Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versushost disease. Leukemia Lymphoma 1996; 24: 71-79.
3. Bianco JA, Higano C, Singer J et al. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. Transplantation 1990; 49: 1194-1195.
4. Ely P, Dunitz J, Rogosheske J et al. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991; 90: 707-710.
5. Ippoliti C, Champlin R, Bugazia N et al. Use of octreotide in the symptomatic management of diarrhea induced by graftversus-host disease in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3350-3354.
6. Wiesmann A, Weller A, Lischka G et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23: 151-155.
7. Greinix HT, Volc-Platzer B, Kalhs P et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426-2431.
8. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
9. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
10. Massenkeil G, Rackwitz S, Genvresse I et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899-903.
11. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNF-alpha antibody. Bone Marrow Transplant 2001; 28: 47-49.
12. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10: 1195-1205.
13. Lee SJ, Zahrieh D, Agura E et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-1564.
14. Marty FM, Lee SJ, Fahey MM et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-2776.
15. Kulkarni S, Powles R, Sirohi B et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32: 165-170.
16. Arora M, Wagner JE, Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265-273.
17. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
18. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397.